mometasone-furoate and Headache

Mometasone furoate nasal spray (MFNS), a potent intranasal corticosteroid with proved efficacy in relieving nasal allergic rhinitis symptoms, has demonstrated effectiveness in improving ocular symptoms associated with seasonal allergic rhinitis (SAR) in retrospective analyses.. We sought to evaluate prospectively the efficacy of MFNS in reducing total ocular symptom scores (TOSSs) and individual ocular symptoms in subjects with SAR.. Subjects 12 years or older (n = 429) with moderate-to-severe baseline symptoms were randomized to MFNS, 200 microg once daily, or placebo in this 15-day, double-blind, parallel-group study. Subjects evaluated morning instantaneous TOSSs and daily reflective TOSSs, total nasal symptom scores (TNSSs; both instantaneous TNSSs and reflective TNSSs, respectively), and individual ocular and nasal symptoms. Mean changes from baseline averaged over days 2 to 15 (instantaneous) and days 1 to 15 (reflective) were calculated. Quality of life was assessed by using the Rhinoconjunctivitis Quality of Life Questionnaire.. MFNS treatment yielded significant reductions from baseline versus placebo in instantaneous TOSSs (-0.34, P = .026, coprimary end point), instantaneous TNSSs (-0.88, P < .001, coprimary end point), reflective TOSSs (-0.44, P = .005), and reflective TNSSs (-1.06, P < .001). Significant decreases in all individual reflective ocular symptoms and instantaneous eye itching/burning and eye watering/tearing were observed for MFNS versus placebo (P < .05). Numeric improvements in instantaneous eye redness were seen but did not reach statistical significance. Improvements in Rhinoconjunctivitis Quality of Life Questionnaire total scores and individual symptom domains were achieved with MFNS treatment versus placebo (P < .001). MFNS was well tolerated.. This prospective study demonstrates that MFNS significantly reduces ocular symptoms in subjects with SAR.

Topics: Administration, Intranasal; Adult; Aerosols; Anti-Allergic Agents; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Mometasone Furoate; Nasal Obstruction; Pregnadienediols; Pruritus; Quality of Life; Retrospective Studies; Rhinitis, Allergic, Seasonal; Tears

Topics: Administration, Intranasal; Aged; Aged, 80 and over; Anti-Allergic Agents; Drug Administration Schedule; Epistaxis; Headache; Humans; Mometasone Furoate; Pharyngitis; Pregnadienediols; Rhinitis, Allergic, Perennial; Treatment Outcome; United States

Mometasone furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children.. To evaluate the efficacy and safety of 2 dosing regimens of mometasone furoate DPI in the treatment of mild-to-moderate persistent asthma in children previously using inhaled corticosteroids (ICSs).. A 12-week, multicenter, double-blind, parallel-group, placebo-controlled study evaluated 2 dosing regimens of mometasone furoate DPI (100 microg every evening and 100 microg twice daily) in 296 children 4 to 11 years old with asthma previously using ICSs. The primary efficacy variable was the change in percentage of predicted forced expiratory volume in 1 second (FEV1) from baseline to end point. Secondary efficacy variables included absolute FEV1, forced expiratory flow between 25% and 75% forced vital capacity, morning and evening peak expiratory flow, asthma symptom scores, albuterol use, nocturnal awakenings, response to therapy, and health-related quality of life.. Mean changes from baseline at end point in predicted FEV1 were 4.73 and 5.52 percentage points for mometasone furoate DPI, 100 microg every evening and 100 microg twice daily, respectively, the difference of which was not significant, and -1.77 percentage points for placebo (P < or = .002). Significant improvements in secondary efficacy variables were also observed for both mometasone furoate DPI treatments over placebo. Both mometasone furoate DPI doses were well tolerated, and no significant differences were noted among the 3 treatment groups in adverse event reporting.. Both mometasone furoate DPI doses were well tolerated and significantly improved lung function, maintained effective asthma control, and improved quality of life in children with asthma.

Topics: Abdominal Pain; Administration, Inhalation; Anti-Allergic Agents; Asthma; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Headache; Humans; Male; Mometasone Furoate; Powders; Pregnadienediols; Quality of Life; Respiratory Function Tests; Spirometry; Treatment Outcome

Topics: Adrenal Cortex Hormones; Headache; Humans; Mometasone Furoate; Nasal Polyps; Olfaction Disorders; Pregnadienediols